Document:

<PAGE>   1

                                                                   EXHIBIT 10.75

                                 AMENDMENT NO. 7

                            DATED AS OF JUNE 1, 2001

                                       TO

                           LOAN AND SECURITY AGREEMENT

                                   AS AMENDED

                            DATED AS OF JUNE 5, 1997

                                      AMONG

                ACCREDO HEALTH, INCORPORATED AND ITS SUBSIDIARIES

                                       AND

                             BANK OF AMERICA, N.A.,

                    FIRST TENNESSEE BANK NATIONAL ASSOCIATION

                                       AND

                          BROWN BROTHERS HARRIMAN & CO.

                                       AND

                         BANK OF AMERICA, N.A., AS AGENT

<PAGE>   2

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                                 Page
                                                                                                                 ----
<S>      <C>       <C>                                                                                           <C>
1.       Definitions.........................................................................................      1

2.       Amendments to Agreement.............................................................................      1

3.       Representations and Warranties......................................................................      2
         3.1.     Incorporation..............................................................................      2
         3.2.     Due Authorization, No Conflicts, Etc.......................................................      2
         3.3.     Due Execution, Etc.........................................................................      3

4.       Conditions Precedent................................................................................      3
         4.1.     Conditions Precedent to Effectiveness of Amendment No. 7...................................      3

5.       Effectiveness of Amendment No. 7....................................................................      4

6.       Closing.............................................................................................      4

7.       Governing Law, Etc..................................................................................      4

8.       Section Titles and Table of Contents................................................................      5

9.       Waiver of Jury Trial................................................................................      5

10.      Counterparts........................................................................................      5

11.      Agreement to Remain in Effect.......................................................................      5
</TABLE>

<PAGE>   3

         AMENDMENT NO. 7 dated as of June 1, 2001 under and to that certain Loan
and Security Agreement dated as of June 5, 1997 as amended by Amendment No. 1
dated August 28, 1998, as further amended by Amendment No. 2 dated March 1,
1999, as further amended by Amendment No. 3 dated as of October 14, 1999,
Amendment No. 4 dated December 3, 1999, Amendment No. 5 dated July 7, 2000 and
as further amended by Amendment No. 6 dated January 1, 2001 (collectively, the
"Agreement"), among Accredo Health, Incorporated (formerly Nova Holdings, Inc.),
a Delaware corporation (the "Borrower"); the Guarantors, jointly and severally;
each of the undersigned Banks (in such capacity, the "Banks"), and Bank of
America, N.A. (successor to NationsBank, N.A.), as Agent for the Banks (in such
capacity, the "Agent").

                                   WITNESSETH:

         WHEREAS, the Borrower, the Guarantors (other than Pharmacare Resources,
Inc. and NCL Management, Inc.), the Banks and the Agent are parties to the
Agreement; and

         WHEREAS, the Borrower, subject to the conditions and provisions of this
Amendment No. 7 being satisfied as hereinafter set forth, is acquiring all of
the outstanding stock of Pharmacare Resources, Inc., a New York corporation
("PRI") and NCL Management, Inc., a New York corporation ("NCL"), pursuant to a
certain Stock Purchase Agreement dated May 31, 2001 between Borrower and the
owners of said New York corporations; and

         WHEREAS, under Section 7.15 of the Agreement, PRI and NCL are, upon
their acquisition by the Borrower, required to enter into the Agreement as
Guarantors hereto and to further execute Guaranty and Suretyship Agreements in
favor of the Agent on behalf of the Banks;

         NOW THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements set forth herein, and for other good and valuable
consideration, the receipt and legal sufficiency of which are hereby
acknowledged, the parties hereto agree to amend the Agreement as follows:

         1.       DEFINITIONS. All capitalized terms used in this Amendment
No. 7 which are not otherwise defined herein shall have the respective meanings
ascribed thereto in the Agreement.

         2.       AMENDMENTS TO AGREEMENT.

                  2.1.     Section I of the Agreement, DEFINITIONS, is hereby
amended by adding thereto the following new definition as follows:

                  "AMENDMENT NO. 7 EFFECTIVE DATE" has the meaning specified in
         Section 5 of this Amendment No. 7.

In addition to the foregoing new definition, the following definition is hereby
amended:

                  "GUARANTOR" is hereby amended to delete AHI Pharmacies, Inc.
         as a Guarantor (it having been merged into Nova Factor, Inc.) and to
         replace the period after subparagraph (F) with a comma, and to add two
         new subparagraphs (G) and (H) as follows:

                           "(G)     Pharmacare Resources, Inc., a New York
         corporation, and

                           (H)      NCL Management, Inc., a New York
         corporation."

                  2.2.     Pharmacare Resources, Inc., a New York corporation,
and NCL Management, Inc., a New York corporation, each hereby agree to become a
party to the Agreement as a Guarantor, and each hereby grants and confirms the
grant of the security interests contained therein.

<PAGE>   4

                  2.3.     Subsection 10.5(A) is hereby amended under the
Borrower's address to replace "1620" with "1640" in front of Century Center
Parkway and to replace "Suite 109" with "Suite 101".

                  2.4.     Exhibits H, I, J, K and L to the Agreement are hereby
deleted and replaced by Exhibits H, I, J, K and L attached hereto, which
replacement exhibits the Borrower and each Guarantor jointly and severally
represent and warrant to the Agents and each Bank to be true and correct as of
the date of this Amendment No. 7.

         3.       REPRESENTATIONS AND WARRANTIES. To induce the Banks and the
Agent to enter into this Amendment No. 7, Borrower and Guarantors jointly and
severally represent and warrant to the Banks and the Agent as follows:

                  3.1.     INCORPORATION. Accredo Health, Incorporated is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware, and is qualified to transact business in the State of
Tennessee; Nova Factor, Inc., Southern Health Systems, Inc., and Hemophilia
Health Services, Inc. (successor to Horizon Health Systems, Inc.) are
corporations duly organized, validly existing and in good standing under the
laws of the State of Tennessee; Sunrise Health Management, Inc., is a
corporation duly organized and validly existing and in good standing under the
laws of the State of Georgia; Childrens Hemophilia Services is a general
partnership duly formed and validly existing under the laws of the State of
California; Pharmacare Resources, Inc. and NCL Management, Inc. are corporations
duly organized, validly existing and in good standing under the laws of the
State of New York; each of the foregoing entities has the lawful power to own
its properties and to engage in the business it now conducts, and each
corporation is duly qualified and in good standing as a foreign corporation in
the jurisdictions wherein the nature of the business transacted by it or
property owned by it is both material and makes qualification necessary; Accredo
Health, Incorporated has its chief executive office and principal place of
business in Memphis, Tennessee, and each of the other entities has its chief
executive office and principal place of business located in either Nashville,
Tennessee or Memphis, Tennessee, except for Sunrise Health Management, Inc.,
which has its principal office in Norcross, Georgia, Childrens Hemophilia
Services which has its principal office in Los Angeles, California, and
Pharmacare Resources, Inc. and NCL Management, Inc. which have their principal
offices in Elmsford, New York.

                  3.2.     DUE AUTHORIZATION, NO CONFLICTS, ETC. The execution,
delivery and performance by the Borrower and Guarantors of this Amendment No. 7
and any and all other agreements, instruments and documents to be executed
and/or delivered by the Borrower or any Guarantor pursuant hereto or in
connection herewith, and the consummation by Borrower and Guarantors of the
transactions contemplated hereby or thereby: (a) are within the corporate and/or
partnership powers of each; (b) have been duly authorized by all necessary
corporate and/or partnership action, including without limitation, the consent
of stockholders/partners where required; (c) do not and will not (i) contravene
the respective certificate of incorporation or by-laws or other comparable
governing documents of Borrower or any Guarantor, (ii) violate any Laws, or any
order or decree of any court or governmental authority, or (iii) conflict with
or result in the breach of, or constitute a default under, or result in the
termination of, any material contractual obligation of Borrower or any
Guarantor, and (d) do not require the consent, authorization by, or approval of,
or notice to, or filing or registration with, any governmental authority or any
other Person other than those which have been obtained and copies of which have
been delivered to the Agent pursuant to Subsection 4.1(a)(ii) hereof, each of
which is in full force and effect.

                  3.3.     DUE EXECUTION, ETC. This Amendment No. 7 and each of
the other agreements, instruments and documents to be executed and/or delivered
by Borrower or any Guarantor pursuant hereto or in connection herewith (a) has
been duly executed and delivered, and (b) constitutes the legal, valid and
binding obligation of each, enforceable against it in accordance with its terms,
subject however to state and federal bankruptcy, insolvency, reorganization and
other laws and general principles of equity affecting enforcement of the rights
of creditors generally.

                                       2

<PAGE>   5

         4.       CONDITIONS PRECEDENT. The effectiveness of this Amendment No.
7 is subject to the fulfillment of the following conditions precedent on or
prior to the Amendment No. 7 Effective Date (as hereinafter defined in Section 5
hereof):

                  4.1.     CONDITIONS PRECEDENT TO EFFECTIVENESS OF AMENDMENT
NO. 7. The Agent shall have received, on or prior to the Amendment No. 7
Effective Date, the following, each dated on or prior to the Amendment No. 7
Effective Date unless otherwise indicated, in form and substance satisfactory to
the Agent and in sufficient copies for each Bank:

                           (a)      Certified copies of (i) the resolutions of
the Board of Directors and/or Partners of Borrower and each Guarantor approving
this Amendment No. 7 and each other agreement, instrument or document to be
executed by them pursuant hereto or as contemplated hereby, and (ii) all
documents evidencing other necessary corporate or partnership action and
required governmental and third party approvals, licenses and consents with
respect to this Amendment No. 7 and the transactions contemplated hereby.

                           (b)      A certificate of the Secretary or an
Assistant Secretary of Borrower and each Guarantor certifying the names and true
signatures of the officers of Borrower and each corporate Guarantor who have
been authorized to execute on behalf of Borrower and such corporate Guarantor
this Amendment No. 7 and any other agreement, instrument or document executed or
to be executed by Borrower and any Guarantor in connection herewith.

                           (c)      A certificate dated the Amendment No. 7
Effective Date signed by the President or any Vice-President of Borrower, to the
following effect:

                           (i)      The representations and warranties of the
         Borrower contained in Sections 3.1, 3.2 and 3.3 of this Amendment No. 7
         are true and correct on and as of such date as though made on and as of
         such date;

                           (ii)     No Default or Event of Default has occurred
         and is continuing, and no Default or Event of Default would result from
         the execution and delivery of this Amendment No. 7 or the other
         agreements, instruments and documents contemplated hereby; and

                           (iii)    The Borrower has paid or agreed to pay all
         amounts payable by it pursuant to the Agreement as amended hereby
         (including, without limitation, all legal fees and expenses of Banks'
         counsel incurred in connection herewith) to the extent then due and
         payable.

                           (d)      Original Guaranty and Suretyship Agreements
duly executed by each of Pharmacare Resources, Inc. and NCL Management, Inc. in
the form attached hereto as EXHIBIT F-1.

                           (e)      Such UCC financing statements and amendments
thereto (including UCC filings to be made in the State of New York) as may be
required by the Banks.

                           (f)      Accession to Stock Pledge Agreement executed
by the Borrower in the form attached hereto as EXHIBIT E-1 together with the
original of all outstanding stock certificates held by Borrower in Pharmacare
Resources, Inc. and NCL Management, Inc., and such blank stock powers as may be
required by the Agent.

         5.       EFFECTIVENESS OF AMENDMENT NO. 7. This Amendment No. 7 and the
Exhibits attached hereto shall become effective at such time as (a) each of the
conditions precedent set forth in Section 4.1 hereof shall have been satisfied,
and (b) counterparts of this Amendment No. 7, executed and delivered by the
Borrower, the Guarantors, the Banks and the Agent shall have been received by
the Agent (or, alternatively, confirmation of the execution hereof by such
parties shall have been received by the Agent). The date upon which the
conditions

                                       3

<PAGE>   6

described in clauses (a) and (b) of the foregoing sentence shall have been
fulfilled is referred to herein as the "Amendment No. 7 Effective Date".

         6.       CLOSING. The Closing under this Amendment No. 7 shall occur on
the Amendment Effective Date at the offices of Boult, Cummings, Conners & Berry,
PLC, 414 Union Street, Nashville, Tennessee 37219, or such other location as the
parties may agree.

         7.       GOVERNING LAW, ETC. This Amendment No. 7 shall be governed by,
and construed in accordance with, the laws of the State of Tennessee as provided
in Section 10.9 of the Agreement, which Section is incorporated herein by
reference and made a part hereof as though set forth in full herein.

         8.       SECTION TITLES AND TABLE OF CONTENTS. The Section Titles and
Table of Contents contained in this Amendment No. 7 are and shall be without
substantive meaning or content of any kind whatsoever and are not a part of the
agreement among the parties hereto.

         9.       WAIVER OF JURY TRIAL. EACH PARTY HERETO, INCLUDING THE
BORROWER, EACH SUBSIDIARY, THE BANKS, AND THE AGENT, HEREBY KNOWINGLY,
VOLUNTARILY AND INTENTIONALLY WAIVE (TO THE EXTENT PERMITTED BY APPLICABLE LAWS)
ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY OF ANY DISPUTE ARISING UNDER,
RELATING TO, OR CONNECTED WITH THIS AGREEMENT, THE COLLATERAL OR ANY OTHER
AGREEMENT, INSTRUMENT OR DOCUMENT CONTEMPLATED HEREBY OR DELIVERED IN CONNECTION
HEREWITH AND AGREE THAT ANY SUCH DISPUTE SHALL BE TRIED BEFORE A JUDGE SITTING
WITHOUT A JURY. THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE BANKS' AND THE
AGENT ENTERING INTO THIS AGREEMENT.

         10.      COUNTERPARTS. This Amendment No. 7 may be executed in any
number of counterparts and by different parties hereto in separate counterparts,
each of which when so executed shall be deemed to be an original and all of
which taken together shall constitute one and the same instrument.

         11.      AGREEMENT TO REMAIN IN EFFECT. Except as expressly provided
herein, the Agreement and each other Collateral Document shall be and shall
continue in full force and effect in accordance with its respective terms.

                                       4

<PAGE>   7

         IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 7
to be executed by their respective officers thereunto duly authorized, as of the
date first above written.

AGENT                                BORROWER
-----                                --------

BANK OF AMERICA, N.A.,               ACCREDO HEALTH, INCORPORATED
as Agent

BY:  /s/  Elizabeth L. Knox          BY:       /s/  Joel R. Kimbrough
   ----------------------------         ----------------------------------------

TITLE:          SVP                  TITLE:               CFO
      -------------------------            -------------------------------------

BANKS                                GUARANTORS AND SUBSIDIARIES
-----                                ---------------------------

BANK OF AMERICA, N.A.                SOUTHERN HEALTH SYSTEMS, INC.

BY:  /s/  Elizabeth L. Knox          BY:       /s/  Joel R. Kimbrough
   ----------------------------         ----------------------------------------

TITLE:         SVP                   TITLE:             CFO
      -------------------------            -------------------------------------

FIRST TENNESSEE BANK NATIONAL        NOVA FACTOR, INC.
ASSOCIATION

BY:    /s/  Bob Nieman               BY:       /s/ Joel R. Kimbrough
   ----------------------------         ----------------------------------------

TITLE: Senior Vice President         TITLE:             CFO
      -------------------------            -------------------------------------

BROWN BROTHERS HARRIMAN & CO.        HEMOPHILIA HEALTH SERVICES, INC.
                                     (successor to Horizon Health Systems, Inc.)

BY:  /s/  Gregory S. Pachus          BY:           /s/ Joel R. Kimbrough
   ----------------------------         ----------------------------------------

TITLE:    Vice President             TITLE:             CFO
      -------------------------            -------------------------------------

                                       5

<PAGE>   8

                                     SUNRISE HEALTH MANAGEMENT, INC.

                                     BY:           /s/ Joel R. Kimbrough
                                        ----------------------------------------

                                     TITLE:                  CFO
                                           -------------------------------------

                                     CHILDRENS HEMOPHILIA SERVICES

                                     BY: Hemophilia Health Services, Inc.,
                                         general partner

                                     BY:         /s/ Joel R. Kimbrough
                                        ----------------------------------------

                                     TITLE:                  CFO
                                           -------------------------------------

                                     PHARMACARE RESOURCES, INC.

                                     BY:           /s/ Joel R. Kimbrough
                                        ----------------------------------------

                                     TITLE:                  CFO
                                           -------------------------------------

                                     NCL MANAGEMENT, INC.

                                     BY:           /s/ Joel R. Kimbrough
                                        ----------------------------------------

                                     TITLE:                  CFO
                                           -------------------------------------

                                       6

<PAGE>   9

                                    EXHIBIT H
                                CORPORATE MATTERS

STATE OF INCORPORATION OF SUBSIDIARIES

         Nova Factor, Inc.                           Tennessee

         Southern Health Systems, Inc.               Tennessee

         Hemophilia Health Services, Inc.            Tennessee

         Sunrise Health Management, Inc.             Georgia

         Pharmacare Resources, Inc.                  New York

         NCL Management, Inc.                        New York

STATES OF QUALIFICATION

         Accredo Health, Incorporated                Tennessee
                                                     California

         Nova Factor, Inc.                           Alabama
                                                     California
                                                     Florida
                                                     Georgia
                                                     Illinois
                                                     Montana
                                                     Texas
                                                     North Carolina

         Hemophilia Health Services, Inc.            California
                                                     Oklahoma

         Pharmacare Resources, Inc.                  New Jersey

STOCK OWNERSHIP

         Accredo Health, Incorporated owns the following outstanding shares of
stock or partnership interests of each Subsidiary listed below:

         Nova Factor, Inc.                   One Hundred Percent (100%) is owned
                                             by Southern Health Systems, Inc.

         Southern Health Systems, Inc.       One Hundred Percent (100%)

         Hemophilia Health Services, Inc.    One Hundred Percent (100%) (as of
                                             June 1, 1997)

         Sunrise Health Management, Inc.     One Hundred Percent (100%) is owned
                                             by Hemophilia Health Services, Inc.

         Pharmacare Resources, Inc.          One Hundred Percent (100%) is owned
                                             by Accredo Health, Incorporated

<PAGE>   10

         NCL Management, Inc.                One Hundred Percent (100%) is owned
                                             by Accredo Health, Incorporated

Children's Hemophilia Services         80% is owned by Hemophilia Health
                                       Services, Inc.

OTHER SUBSIDIARIES

A.       Nova Factor, Inc. has the following partnership interests:

         Texas Health Pharmaceutical Resources:        Equity Ownership of 50%

         Teddy Bear Home Care - Drug Therapies,
         d/b/a Cook Children's Home Health:            Equity Ownership of 50%

         Children's Memorial Home Hemophilia Services
         d/b/a CM Factorcare:                          Equity Ownership of 50%

         Children's Home Services                      Equity Ownership of 50%

         Children's Biotech Pharmacy Services          Equity Ownership of 50%

B.       Hemophilia Health Services has the following partnership interests:

         Specialized Pharmacy Services:                Equity Ownership of 50%

         Children's National Hemophilia Care           Equity Ownership of 50%

                                       2

<PAGE>   11

                                    EXHIBIT I
                                    ADDRESSES

         THE FOLLOWING ARE THE ADDRESSES OF ALL OF THE PLACES OF BUSINESS OF THE
BORROWER AND EACH SUBSIDIARY AS DEFINED IN THE LOAN AND SECURITY AGREEMENT:

         Accredo Health, Incorporated
         1640 Century Center Parkway
         Suites 101, 103, 104, 105
         Memphis, Tennessee  38134

         Nova Factor, Inc.
         1620 Century Center Parkway
         Suite 101-110
         Memphis, Tennessee  38134

         Nova Factor, Inc.
         3576 Lorna Ridge Drive
         Hoover, Alabama  35216

         Southern Health Systems, Inc.
         1640 Century Center Parkway
         Suite 101
         Memphis, Tennessee  38134

         Hemophilia Health Services, Inc.
         6820 Charlotte Pike
         Suite 100
         Nashville, Tennessee  37209

         Pharmacare Resources, Inc.
         8 Westchester Plaza
         Elmsford, New York  10523

         NCL Management, Inc.
         8 Westchester Plaza
         Elmsford, New York  10523

         Texas Health Pharmaceutical Resources
         2100 Hwy. 360, Suite 604
         Grand Prairie, Texas  75050

         Teddy Bear Home Care/Drug Therapies
         d/b/a Cook Childrens Home Health
         2100 Hwy. 360, Suite 605A
         Grand Prairie, Texas  75050

         Children's Memorial Home Hemophilia Services
         d/b/a CM Factorcare
         1620 Century Center Parkway
         Suite 109
         Memphis, Tennessee  38134

<PAGE>   12

         Sunrise Health Management, Inc.
         5980-E, F, G & H Unity Drive
         Norcross, Georgia  30071

         Nova Factor, Inc.
         5393 Roosevelt Blvd.
         Jacksonville, Florida  32210

         Nova Factor, Inc.
         11562 Knott Avenue
         Unit 6
         Garden Grove, California  92841

         Nova Factor, Inc.
         9741 A Southern Pine
         Charlotte, North Carolina  28273

         Childrens Hemophilia Services
         6820 Charlotte Pike
         Suite 100
         Nashville, Tennessee  37209

         Children's Home Services
         1620 Century Center Parkway
         Suite 109
         Memphis, Tennessee  38134

         Specialized Pharmaceutical Services, Inc.
         6820 Charlotte Pike
         Suite 100
         Nashville, Tennessee  37209

         Children's National Hemophilia Care
         6820 Charlotte Pike
         Suite 100
         Nashville, Tennessee  37209

         Children's Biotech Pharmacy Services
         1620 Century Center Parkway
         Suite 109
         Memphis, Tennessee  38134

                                       2

<PAGE>   13

                              INVENTORY LOCATIONS

The following are the addresses of all of the inventory locations of the
Borrower and each subsidiary as defined in the Loan and Security Agreement:

<TABLE>
<CAPTION>
                                                     Owner of                           Inventory*(1)
Address                                              Inventory                          Amount
-------                                              ---------                          -------------
<S>                                                  <C>                                <C>
Nova Factor, Inc.                                    Nova Factor, Inc.                  $15,000,000.00
1620 Century Center Pkwy.
Suite 109
Memphis, TN  38134

Nova Factor, Inc.                                    NFI                                $1,100,000.00
3576 Lorna Ridge Drive
Hoover, AL  35216

Hemophilia Health Services, Inc.                     HHS                                $7,000,000.00
6820 Charlotte Pike
Suite 100
Nashville, TN  37209

Texas Health Pharmaceutical Resources                NFI                                $1,100,000.00
Nova Factor -- Dallas
Cook Children's Home Health
2100 Hwy. 360, Suite 604
Grand Prairie, TX  75050

Nova Factor, Inc.                                    AHI                                $500,000.00
11562 Knott Avenue
Unit 6
Garden Grove, California  92841

Nova Factor, Inc.                                    AHI                                $600,000.00
5393 Roosevelt Blvd.
Suite 21
Jacksonville, Florida  32210

Nova Factor, Inc.                                    AHI                                $500,000.00
9741 A Southern Pine
Charlotte, North Carolina  28273

Sunrise Health Management, Inc.                      SHM                                $750,000.00
5980-G Unity Drive
Norcross, GA  30071

Dallas Children's Hospital                           NFI/HHS                            $200,000.00
1935 Motor Street
Dallas, TX  75235

A.I. Dupont Hospital for Children                    NFI                                $50,000.00
1600 Rockland Road
Wilmington, DE  19899
</TABLE>

                                       3

<PAGE>   14

<TABLE>
<S>                                                  <C>                                <C>
Childrens Home Care                                  NFI/HHS                            $100,000.00
4650 Sunset Blvd.
Mailstop #16
Los Angeles, CA  90027

Childrens Hospital of Oklahoma                       HHS                                $100,000.00
940 NE 19th Street
Oklahoma City, OK  73126

University Pharmacy of Oklahoma                      HHS                                $175,000.00
835 Station L Young Blvd.
Oklahoma City, OK  73104

LeBonheur Childrens Hospital                         HHS                                $20,000.00
848 Adams
Memphis, Tennessee  38103

St. Vincent Mercy Medical Center                     HHS                                $10,000.00
Ohio

Pharmacare Resources, Inc.
8 Westchester Plaza
Elmsford, New York  10523                            PRI                                $1,000,000.00
</TABLE>

*(1)     Please note that these inventory balances will fluctuate from month to
         month.

                                       4

<PAGE>   15

                                    EXHIBIT J
                              LITIGATION AND CLAIMS

1.       Judy Merritt v. Darryl Hunter, PharmaThera, Inc. and Southern Health
         Systems, Inc. (Southern Health Systems, Inc.) -- This lawsuit was filed
         in the Circuit Court of Shelby County, Tennessee for the Thirtieth
         Judicial District at Memphis on August 29, 1995, cause number 72254
         T.D. 95. This is a negligence lawsuit arising out of an automobile
         accident involving a van owned by PharmaThera, Inc. and driven by a
         Southern Health Systems, Inc. employee. Plaintiff seeks medical
         expenses, lost wages, loss of earning capacity, pain and suffering,
         etc. and has requested a jury trial.

2.       Workers Compensation Claims -- From time to time, Nova Factor, Inc.
         receives claims for workers compensation in the normal course of
         business. Nova Factor, Inc. maintains workers compensation insurance
         through Travelers Insurance Company and the workers compensation claims
         are being handled by Travelers.

<PAGE>   16

                                    EXHIBIT K
                              COMPLIANCE WITH LAWS

         Nova Factor, Inc. and Hemophilia Health Services, Inc. historically
have entered into partnerships and other agreements with various physicians,
home health agencies and hospitals. Those activities, practices, procedures and
arrangements have been consistent with contemporaneous industry practices and
norms with respect to compliance with Medicare/Medicaid fraud and abuse statutes
and regulations, the federal prohibitions against physician referrals, commonly
referred to as Stark I and Stark II, and state corporate practice of medicine,
fee-splitting and anti-referral statutes, regulations and policies.
Additionally, some of those arrangements predate the adoption of the "safe
harbors", and, therefor not all of those arrangements currently fit within a
known "safe harbor".

         While the Borrower and the Subsidiaries have at all times attempted to
comply with all applicable laws, Borrower and the Subsidiaries cannot foreclose
the possibility that their activities could be challenged by a governmental
agency. If challenged, Borrower and the Subsidiaries believe that their actions
are defendable.

<PAGE>   17

                                    EXHIBIT L
                   MATERIAL LEASES, CONTRACTS AND COMMITMENTS

1.       Nova Factor, Inc. has distribution agreements with Genzyme Corporation,
         Genentech Managed Distribution System, Biogen, Inc., Genentech, Inc.,
         Centocor, Inc., MedImmune, Inc., Allergan, Inc. and all manufacturers
         of clotting factor.

2.       Accredo Health, Incorporated has employment agreements with the
         following individuals: Kyle Callahan, David Stevens, John R. Grow, Joel
         Kimbrough and Thomas W. Bell, Jr.

3.       Nova Factor, Inc. has the following partnership agreements:

         (a)      Teddy Bear Home Care Drug Therapies, d/b/a Cook Children's
                  Home Health, is a general partnership formed under the laws of
                  the State of Texas; NFI has an equity ownership of 50%; other
                  partner is Cook Children's Medical Center with a 50% equity
                  interest.
         (b)      Texas Health Pharmaceutical Resources is a general partnership
                  formed under the laws of the State of Texas; NFI has equity
                  ownership of 50%; other partner is Alternative Care Systems,
                  Inc. with a 50% equity interest.
         (c)      Children's Memorial Home Hemophilia Services' partnership
                  d/b/a CM FactorCare, is a general partnership formed under the
                  laws of the State of Tennessee; NFI has an equity ownership of
                  50%; other partner is CM Healthcare Resources, Inc. with a 50%
                  equity interest.
         (d)      Children's Home Services.
         (e)      Children's Biotech Pharmacy Services

4.       Hemophilia Health Services, Inc. has the following partnership
         agreements:

         (a)      Specialized Pharmacy Services
         (b)      Childrens Hemophilia Services
         (c)      Children's National Hemophilia Care

5.       Nova Factor, Inc. has management, sales and/or service agreement with
         Texas Health Pharmaceutical Resources, Teddy Bear Home Care Drug
         Therapies d/b/a Cook Children's Home Health and Children's Memorial
         Home Hemophilia Services d/b/a CM FactorCare, Childrens Home Services
         and Childrens Biotech Pharmacy Services.

6.       HHS has management sales and/or service agreements with Specialized
         Pharmacy Services, Childrens Hemophilia Services and Children's
         National Hemophilia Care.

7.       Accredo Health, Incorporated has two stock option plans, an employee
         stock purchase plan, a 401(k) plan, and a cafeteria (health benefits)
         plan.

8.       Nova Factor, Inc., Hemophilia Health Services, Inc., Pharmacare
         Resources, Inc., NCL Management, Inc. and Sunrise Health Management,
         Inc. have informal employee bonus plans and other incentive plans in
         the ordinary course of business.

9.       Nova Factor, Inc., Hemophilia Health Services, Inc., Pharmacare
         Resources, Inc., NCL Management, Inc., AHI Pharmacies, Inc. and Sunrise
         Health Management, Inc. have managed care contracts, Medicare contracts
         and Medicaid contracts.
<PAGE>   18
10.      Hemophilia Health Services, Inc. has contracts with Bronson Hospital in
         Michigan for said hospital to supply services for a fee.

11.      Nova Factor, Inc. and Hemophilia Health Services, Inc. have pharmacy
         contracts.

12.      Nova Factor, Inc., Hemophilia Health Services, Inc., Pharmacare
         Resources, Inc., NCL Management, Inc. and Sunrise Health Management,
         Inc. have confidentiality and noncompete agreements with various
         employees.

13.      Hemophilia Health Services, Inc. leases the following:

         (a)      Real property at 6820 Charlotte Pike, Nashville, Tennessee
                  37209;

14.      Nova Factor, Inc. leases real estate at 1620 Century Center Parkway,
         Suites      and 109, Memphis, Tennessee 38134, 1640 Century Center
         Parkway, Suites 101, 103 and      , Memphis, Tennessee 38134 and real
         estate at 3576 Lorna Ridge Drive, Hoover, Alabama 35216.

15.      Teddy Bear Home Care Drug Therapies d/b/a Cook Children's Home Health
         leases real property at 2100 Hwy. 360, Suite 605A, Grand Prairie, Texas
         75050.

16.      Nova Factor, Inc. leases real property at 5393 Roosevelt Blvd.,
         Suite 21, Jacksonville, Florida 32210; 9741 A Southern Pine, Charlotte,
         North Carolina 28273; and 11562 Knott Avenue, Unit 6, Garden Grove,
         California 92841.

17.      Sunrise Health Management, Inc. leases real property at 5980-E, F, G &
         H Unity Drive, Norcross, Georgia 30071.

18.      Pharmacare Resources, Inc. and NCL Management, Inc. leases real
         property at 8 Westchester Plaza, Elmsford, New York 10523

19.      Sunrise Health Management, Inc. has a management agreement with
         Specialized Pharmacy Services.

20.      Accredo has filed lists of material contracts with the Securities and
         Exchange Commission. A copy of the lists of these contracts are
         attached hereto and incorporated herein by reference.

                                       2<PAGE>   1

                                                                   EXHIBIT 10.76

        AMENDMENT NO. 1 TO AMENDED AND RESTATED CONTRACT FOR THE SALE AND
                 DISTRIBUTION OF GENENTECH HUMAN GROWTH HORMONE

This Amendment No. 1 is entered into by and between Genentech, Inc., a Delaware
corporation, with offices at 1 DNA Way, South San Francisco, California 94080
("Genentech") and Nova Factor, Inc., a Tennessee corporation located at 1620
Century Center Parkway, Suite 109, Memphis, Tennessee 38134 ("Nova Factor") for
the purpose of amending that certain Amended and Restated Contract for the Sale
and Distribution of Genentech Human Growth Hormone between Genentech and Nova
Factor effective April 8, 2000 ("Agreement"). Genentech and Nova Factor are
collectively referred to hereinafter as the ("Parties"), or individually as a
("Party").

Genentech and Nova Factor now wish to amend certain terms of the Agreement as
described below. Accordingly, the parties hereby agree to amend the Agreement as
follows:

1.       Subsection 10(a) is hereby deleted in its entirety and replaced with
         the following language:

         10.      Distribution of Genentech HGH

         (a)      Dispensing Obligation. In accordance with applicable laws and
         regulations, Nova Factor shall evaluate the reimbursement status of,
         and dispense Genentech HGH to, all patients with a prescription for
         Genentech HGH who are referred by any person or entity to Nova Factor.
         Within three (3) business days of Nova Factor's receipt of each
         prescription or other appropriate shipment request, Nova Factor shall
         dispense Genentech HGH to patients without regard to third party payor
         coverage of such patient's Genentech HGH; provided, however, that if
         the patient or physician specifically requests a delay in dispensing or
         if prior authorization is required for a Government Program patient,
         both as documented by written records of Nova Factor, said three (3)
         day time period for shipping shall not apply, and Nova Factor shall use
         its commercially reasonable best efforts to ship the requested
         Genentech HGH within thirty (30) days of such prescription or shipment
         request. Notwithstanding the preceding provisions, Nova Factor shall
         not dispense Genentech HGH if the patient has drug on hand at the time
         of the referral. If prior authorization is required, regardless of
         whether the payor is a Government Program or not, Nova Factor shall
         [***] As [***] within three (3) days of the referral to Nova Factor,
         the three (3) day time period [***].

2.       Exhibit L is hereby deleted and replaced by Exhibit L attached hereto
         and incorporated into the Agreement.

3.       This Amendment No. 1 shall be effective upon execution by all of the
         parties hereto.

4.       All terms in this Agreement with initial capitalization shall have the
         meanings assigned to such terms herein or in the Agreement.

5.       The remaining terms and conditions of the Agreement shall remain in
         full force and effect.

<PAGE>   2

IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to be
duly executed by their respective officers or representatives duly authorized so
to do.

NOVA FACTOR, INC.                         GENENTECH, INC.

By:       /s/  Randy Grow                 By:       /s/  Diane Parks
   ----------------------------------        -----------------------------------

Name:          Randy Grow                 Name:          Diane Parks
     --------------------------------          ---------------------------------

Title:      President                        Vice President, Managed Care and
      -------------------------------        Commercial Support
                                             -----------------------------------

Date:             6/01/01                 Date:          8/08/01
     --------------------------------          ---------------------------------

1620 Century Center Parkway, Ste. 109     1 DNA Way
Memphis, TN  38134                        South San Francisco, CA  94080
(901) 385-3745                            (650) 225-1000

Notices to be Addressed to:               Notices to be Addressed to:
President                                 Vice President, Managed Care and
                                          Commercial Support

                                          With a copy to:
                                          Corporate Secretary

                                       2

<PAGE>   3

                                    EXHIBIT L

                              PERFORMANCE STANDARDS

Nova Factor shall monitor data elements and status codes on all patients
receiving Genentech HGH. Performance will be monitored on all patients receiving
Genentech HGH except patients with diagnosis codes relating to infertility.
Patients receiving Genentech HGH through the [***] program shall have their
first shipment from Nova Factor measured as a maintenance shipment. Genentech's
[***] program shall notify Nova Factor at least seven (7) calendar days in
advance of the expected exhaust date of patients who have previously received a
starter kit and have chosen Nova Factor as the designated provider of service.

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------------
   Performance                     Optimal              Standard             Suboptimal           Failure to Meet
    Standard                                                                                        Standard
----------------------------------------------------------------------------------------------------------------------
<S>                       <C>                    <C>                     <C>                    <C>
#1 Time to verify         At least 90%           80-89% within 72        75-79% within 72       <75% within 72
coverage                  Within 72 hours        hours                   hours                  hours
----------------------------------------------------------------------------------------------------------------------
#2 Time to Ship           At least 90%           80-89% within 72        75-79% within 72       <75% within 72
                          within 72 hrs. of      hours of referral       hours of referral      hours of referral
                          referral date for      date for initial        date for initial       date for initial
                          initial shipment       shipment and 72         shipment and 72        shipment and 72
                          and 72 hours           hours prior to          hours prior to         hours prior to
                          prior to exhaust       exhaust for             exhaust for            exhaust for
                          for maintenance        maintenance             maintenance            maintenance
                          patients               patients                patients               patients
----------------------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>   4

                               EXHIBIT L (cont.'d)

                      DESCRIPTION OF PERFORMANCE STANDARDS

[***]

                                       2

<PAGE>   5

                               EXHIBIT L (cont.'d)

Assumptions/Definitions

[***]

                                       3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}]]